Research analysts at StockNews.com started coverage on shares of BiondVax Pharmaceuticals (NASDAQ:BVXV – Get Rating) in a research report issued to clients and investors on Monday. The brokerage set a "sell" rating on the stock.
BiondVax Pharmaceuticals Trading Up 7.6 %
NASDAQ BVXV opened at $2.82 on Monday. The business's fifty day moving average is $6.78 and its 200-day moving average is $8.93. The company has a debt-to-equity ratio of 5.92, a current ratio of 5.76 and a quick ratio of 5.76. The stock has a market capitalization of $4.04 million, a price-to-earnings ratio of -0.70 and a beta of 2.65. BiondVax Pharmaceuticals has a one year low of $2.37 and a one year high of $22.90.
Get BiondVax Pharmaceuticals alerts:BiondVax Pharmaceuticals (NASDAQ:BVXV – Get Rating) last announced its quarterly earnings data on Wednesday, November 30th. The company reported $0.06 EPS for the quarter, topping the consensus estimate of ($0.10) by $0.16. Equities research analysts predict that BiondVax Pharmaceuticals will post -0.3 EPS for the current year.
Hedge Funds Weigh In On BiondVax Pharmaceuticals
An institutional investor recently raised its position in BiondVax Pharmaceuticals stock. Envestnet Asset Management Inc. grew its position in shares of BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV – Get Rating) by 226.8% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 163,423 shares of the company's stock after buying an additional 113,418 shares during the period. Envestnet Asset Management Inc. owned 1.44% of BiondVax Pharmaceuticals worth $191,000 at the end of the most recent reporting period.BiondVax Pharmaceuticals Company Profile
(Get Rating)
BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious diseases and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications.
See Also
- Get a free copy of the StockNews.com research report on BiondVax Pharmaceuticals (BVXV)
- General Electric Stock, The Sum of All Parts Strategy is Paying Off
- MarketBeat: Week in Review 01/09-01/13
- JPMorgan Chase Falls As Banks Brace For Recession
- Why is the Bed Bath & Beyond Stock Price up 261%?
- Roku Stock Price is Trending, Here's Why
Receive News & Ratings for BiondVax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BiondVax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.